Néovacs and UTCBS Secure €80,000 for Their LNPReg Project
The biopharmaceutical company based in Suresnes announced on September 30, 2026 that it has received Lab&Co funding, operated by the ValoCité University Innovation Hub as part of France 2030. This support aims to strengthen its academic collaboration around messenger RNA-based therapies.
Dedicated Funding for the LNPReg Project on Lipid Nanoparticles
The ValoCité valuation committee awarded a Lab&Co grant of €80,000 to the LNPReg project, led by Drs Nathalie Mignet, head of the Unit of Chemical and Biological Technologies for Health (UTCBS, CNRS/UPC/Inserm), and Katia Lemdani, R&D Director of Néovacs.
This project aims to develop new lipid nanoparticles (LNPs) enabling the regulation of immune response in autoimmune diseases. According to the statement, this approach seeks to study the inflammatory profile of new LNPs in order to adapt their use to the disease profile to be treated.
The support is intended to sustain the existing partnership between the two entities, with a stated ambition to create a joint laboratory in the long term.
Collaboration Underway Since 2024 and Patent Filed in 2026
Néovacs and the UTCBS laboratory began collaboration in May 2024 for the design of new lipids intended for messenger RNA formulation, in order to induce an antibody response against cytokines overexpressed in chronic inflammatory diseases.
This joint work resulted in the filing of a patent application in 2026, protecting a new family of proprietary lipids intended for the delivery of therapeutic molecules based on mRNA.
Néovacs is providing additional funding of approximately €40,000 and will in return benefit from an exclusive and worldwide exploitation right over the lipids used in the formulation of mRNA therapies for the induction of regulatory T cell responses. Nathalie Mignet emphasized the value of exchanges between academic and private research: "The laboratory brings its scientific expertise, while the company plays a key role in the valorization of results and their development towards therapeutic potential."
